Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...
Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...
Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...
Sanofi CFO François Roger signals increased M&A activity, eyes China for innovation, as company expects cash from Opella sale and plans €5B share buyback.
Fertility startup Gameto has received permission from the FDA to see if its ovary-in-a-dish technology can make in vitro ...
VC, a venture capital firm that has spread its bets across multiple industries, including biotech and digital health, is ...
Teva CEO Richard Francis expects continued growth for Austedo despite future Medicare price negotiations, maintaining $2.5B ...
The Trump administration said on Wednesday it will consider “opportunities to bring greater transparency” to the ...
The first of two confirmation hearings is now underway for Robert F. Kennedy, Jr. to serve as President Donald Trump’s HHS ...
Embattled genetics testing giant 23andMe is thinking of selling itself as it runs out of cash. The company needs ...
Curie.Bio reveals $340M seed fund, Cullinan's zipalertinib succeeds in lung cancer trial, Benchling cuts 10% staff, I-Mab reduces workforce, Regulus shares Phase 1b data, Imvax raises $29M ...
Lonza said Wednesday morning it is on the hunt for deals to increase its capacity and technology offerings, which comes after ...